Group 1 - The wearable medical devices industry is experiencing rapid growth driven by technological advancements, product innovation, remote monitoring, home healthcare, and increased health awareness, with the global market expected to reach USD 42.74 billion in 2024 and grow to USD 168.29 billion by 2030, representing a compound annual growth rate (CAGR) of 25.53% [2][8][10] - In China, the wearable device market is the largest globally, with a year-on-year sales increase of 41.0% in January 2025, driven by the "National Subsidy" policy, which significantly boosted sales of smartwatches and wristbands by 33.7% and 68.0% respectively [9][10] - The market is benefiting from enhanced product cost-performance due to subsidies and promotions, leading to increased demand for both replacement and new users, particularly in the price segments of RMB 500-2000, which saw sales growth rates of 83.1%, 112.3%, and 77.0% respectively [9][10] Group 2 - The wearable medical devices encompass various forms such as headbands, necklaces, glasses, smartwatches, and wristbands, which monitor parameters like heart rate, sleep, and blood pressure, utilizing optical sensors for blood pressure and blood component monitoring [7][8] - Despite the rapid development, the industry faces challenges including data security, lack of unified standards, and issues with monitoring data accuracy and medical device certification [10] - The industry is entering a phase of accelerated development characterized by policy support and consumption upgrades, positioning wearable medical devices as a crucial component in health monitoring and intervention treatment [2][10]

Core Insights - The China International Import Expo (CIIE) serves as a vital platform for global innovation to enter the Chinese market, with companies like Edwards Lifesciences leveraging it to enhance local partnerships and accelerate the clinical application of innovative medical technologies [1][2] - Edwards has witnessed significant growth in the Chinese medical industry over the past 25 years, benefiting from an improved business environment and innovative regulatory breakthroughs [1] - The company plans to expand its local collaboration network and deepen partnerships with clinical experts to enhance the treatment of structural heart diseases in China [1] Company Highlights - Edwards Lifesciences has successfully transitioned multiple innovative products from exhibition to clinical application, including the INSPIRIS RESILIA valve launched in 2021 and the SAPIEN3 Ultra RESILIA valve, which debuted at the 2023 CIIE [1] - The MITRIS RESILIA valve was officially launched in China in April 2023, showcasing the rapid commercialization of products introduced at the expo [1] - The PASCAL Precision transcatheter valve repair system made its debut at the CIIE after being launched in Hong Kong [1] Other Company Activities - This year marks the sixth consecutive participation of Edwards at the CIIE, where it showcases a full range of cutting-edge products and treatment solutions, including an interactive experience area for participants [2] - AstraZeneca, Novo Nordisk, and Intuitive Surgical are also notable participants, with AstraZeneca planning to announce a new production expansion plan and showcasing over 40 innovative drugs [2] - Novo Nordisk is focusing on obesity management with an immersive experience space, highlighting the importance of public awareness regarding obesity [2] Product Innovations - Novo Nordisk will present advancements in its "semaglutide family" of products, including the approval of new indications for chronic kidney disease and the introduction of oral formulations [3] - Intuitive Surgical will showcase its da Vinci surgical robots, emphasizing its commitment to innovation in medical technology and the Chinese market [3] - The company aims to build a comprehensive training system for hospitals and doctors to enhance their skills in robotic surgery [3]